Falkland Islands Science Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Falkland Islands Science Times.

Press releases published on September 30, 2026

Sep. 30, 2026

Rezera Announces Phase 1 Results for Trabzanoflast, which was Generally Well Tolerated and Demonstrated High Central Nervous System Exposure (CNS)

Indeterminate GlobeNewswire

Sep. 30, 2026

ROC Advances to Global Leader for Age Estimation Accuracy in NIST FATE AEV

Indeterminate GlobeNewswire

Sep. 30, 2026

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Indeterminate GlobeNewswire

Sep. 30, 2026

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Indeterminate GlobeNewswire

Sep. 30, 2026

Parabolic Announces $9.3 Million in Annualized Cost Savings from ConnectAndSell Integration and Business Unit Realignment

Indeterminate GlobeNewswire

Sep. 30, 2026

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Indeterminate GlobeNewswire

Sep. 30, 2026

Cycurion Discusses Record Contract Win, Public Safety Expansion and Growth Strategy in New Interview

Indeterminate GlobeNewswire

Sep. 30, 2026

Federal Court Rules in Favor of Genius Group, Denying All Motions to Dismiss in RICO Lawsuit

Indeterminate GlobeNewswire

Sep. 30, 2026

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

Indeterminate GlobeNewswire

Sep. 30, 2026

AGM Group Advances AI Inference Strategy, Storage Integration and Server Deliveries

Indeterminate GlobeNewswire

Sep. 30, 2026

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Indeterminate GlobeNewswire

Sep. 30, 2026

Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings

Indeterminate GlobeNewswire

Sep. 30, 2026

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Indeterminate GlobeNewswire

Sep. 30, 2026

Ocugen to Participate in Upcoming Scientific Conferences

Indeterminate GlobeNewswire

Sep. 30, 2026

R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia

Indeterminate GlobeNewswire

Sep. 30, 2026

EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application

Indeterminate GlobeNewswire

Sep. 30, 2026

More Than 1,600 Participants Anchor Calroy Health Sciences' Joint Formulation Research

Indeterminate GlobeNewswire

Sep. 30, 2026

FactSet Reports Results for Fourth Quarter and Fiscal 2026

Indeterminate GlobeNewswire

Sep. 30, 2026

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

Indeterminate GlobeNewswire

Sep. 30, 2026

Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury

Indeterminate GlobeNewswire